| Autor: |
KUMAR, BHARGAVI, THANGAVELU, SARAVANAN, SELVAM, SAKTHIVEL, RAJA, VIKRANTH, CHANDRAN, ADITYA |
| Předmět: |
|
| Zdroj: |
Journal of Clinical & Diagnostic Research; Sep2022, Vol. 16 Issue 9, p9-11, 3p |
| Abstrakt: |
While policy makers around the globe have meticulously organised mass immunisation against Coronavirus Disease 2019 (COVID- 19), its safety concerns and adverse events that need prompt evaluation are also emerging. Acute Transverse Myelitis (TM) is a rare neurological phenomenon where motor, sensory or autonomic disturbance occurs as a result of spinal cord injury. The aetiology of transverse myelitis is thought to be immune-mediated as a result of infection, parainfectious disorder, autoimmune disease or malignancy. Though a rare disease, acute TM warrants prompt recognition and aggressive therapy for favourable neurological patient outcomes. Hereby, authors presented this case of a 61-year-old male patient who developed symptoms of acute TM, 20 days after receiving an adenovirus vectored ChAdOx1 nCoV-19 vaccine against SARS-CoV-2. The patient was treated with intravenous steroids, supportive care with Foley's catheterisation and his weakness and bladder control improved over 1 week. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
